Eli Lilly in Talks to Acquire Ventyx Biosciences in USD 1 Billion-Plus Deal
A potential buyout of Ventyx will add drugs for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis to Lilly's pipeline, along with treatments for conditions like Parkinson's.
Bengaluru: Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than USD 1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Shares of Ventyx surged more than 50% in extended trading following the report, which said the deal could be announced imminently.
Also Read: Novo Nordisk Bets on Oral Wegovy to Take on Eli Lilly in US Obesity Market
A potential buyout of Ventyx will add drugs for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis to Lilly's pipeline, along with treatments for conditions like Parkinson's.
One of Ventyx's experimental drugs is currently in mid-stage development for the treatment of a cardiovascular disease associated with obesity.
